UK’s Shrinking Substance Portfolio: Threat or Turning Point?

The UK is experiencing a decline in the availability of active substances, which raises both risks and opportunities for the biocides and chemicals sector. Across the EU and UK, the number of approved actives has been shrinking, with certain product types (PTs) impacted more severely than others. This trend is driven by high costs and investment requirements, evolving regulatory obligations such as endocrine disruptor (ED) criteria, and tight timelines for compliance. The impact is significant: reduced biocidal product (BP) availability, potential gaps in market coverage, and challenges to resistance management strategies that are critical for meeting sustainability goals (SDGs). These pressures could also affect essential functions in public health and industry. For companies, this situation demands proactive measures. Opportunities exist to mitigate risk through regulatory monitoring, horizon scanning of product portfolios, and active participation in public consultations to influence decisions and provide information on alternatives. Collaboration within the industry may also open pathways to share costs and maintain market access. Ultimately, the response depends on each stakeholder’s role in the supply chain, but staying informed and engaged is key to turning this challenge into a strategic advantage.